4SC receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL in the European Union
- The European Medicines Agency (EMA) has granted Orphan Drug Designation for resminostat for treatment of cutaneous T-cell lymphoma (CTCL)
- ODD benefits include 10 years’ market exclusivity in the European Union
- The Marketing Authorisation Application (MAA) for Kinselby (resminostat) in the EU remains on track for filing in Q1 2024
Planegg-Martinsried, Germany, 18 October 2023 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage CTCL, received notification from the European Medicines Agency (EMA) that it has granted Orphan Drug Designation (ODD) to resminostat for the treatment of cutaneous T-cell lymphoma (CTCL).
